设为首页 加入收藏

TOP

CANCIDAS 50 mg powder for concentrate for solution forinfusi
2015-03-03 16:37:46 来源: 作者: 【 】 浏览:378次 评论:0

For doctors

 

What is it and how is it used?

CANCIDAS is an antifungal medicine that interferes with the production of a component (glucan polysaccharide) of the fungal cell wall that is necessary if the fungus is to continue living and growing. Fungal cells exposed to CANCIDAS have incomplete or defective cell walls, making them fragile and unable to grow.

CANCIDAS may have been prescribed to treat a serious fungal infection called invasive candidiasis. The infection is caused by fungal (yeast) cells called Candida. These yeast cells are normally found in the digestive tract, and do not cause an infection unless they enter the bloodstream (in which case the infection is referred to as candidaemia) or other tissues or organs, such as the lining of the abdomen (peritonitis), the heart, the kidneys, the liver, bones, muscles, joints, spleen, or eyes. Persons at high risk for invasive candidiasis include surgical patients and those whose immune systems are deficient. Fever and chills that do not respond to antibacterial therapy are the most common symptoms of this type of infection.

Alternatively, your doctor may have prescribed CANCIDAS to treat a fungal infection in your nose, nasal sinuses, or lungs because other antifungal treatments have not been working as well as expected or because the other antifungal treatments are causing side effects. This infection is caused by organisms called Aspergillus. Aspergillus fungal infections begin in the respiratory system (in the nose, sinuses, or lungs) because the spores of the fungus are found in the air we breathe every day. This infection is named invasive aspergillosis. It is possible for the fungus to spread to other tissues and organs. In most healthy individuals, the natural ability to fight disease destroys the spores and removes them from the body. Some medical conditions lower the body’s resistance to diseases. Also, certain medicines prescribed for patients who are organ or bone marrow recipients lower the body’s resistance to diseases. These are the patients who are most likely to develop an Aspergillus infection.

Persistent fever due to infection may occur following chemotherapy or medical conditions that lower the body’s resistance to disease by lowering counts of certain white blood cells. If the fever is not reduced by treatment with an antibiotic, your doctor may suspect that you have a fungal infection and prescribe CANCIDAS to treat it.

What do you have to consider before using it?

Do not take CANCIDAS

Take special care with CANCIDAS

Tell your doctor about any medical conditions you have or have had.

Children and Adolescents

CANCIDAS has been approved for use in children and adolescents for all the infection types described above. The dose used in paediatric patients may differ from the dose used in adult patients.

Taking other medicines

Your physician will determine if any adjustments should be made to other medicines you may be taking. If you are receiving cyclosporine, your physician may order additional blood tests during your treatment.

Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without a prescription. It is particularly important for your doctor to know if you are taking certain anti-HIV medicines (including efavirenz or nevirapine), the antiseizure (epilepsy) medicines phenytoin and carbamazepine, the steroid dexamethasone, the antibiotic rifampicin, and the immunosuppressant tacrolimus.

Pregnancy and breastfeeding

CANCIDAS has not been studied in pregnant women, and should be used in pregnancy only if the potential benefit justifies the potential risk to the foetus. Women receiving CANCIDAS should not breast-feed.
Ask your doctor for advice before taking any medicine.

Driving and using machines

There is no information to suggest that CANCIDAS affects your ability to drive or operate machinery.

Important information about some of the ingredients of CANCIDAS

CANCIDAS contains sucrose. If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine.

How is it used?

CANCIDAS will always be prepared and given to you by a doctor or another healthcare professional.

CANCIDAS should be administered once daily by slow intravenous infusion over approximately 1 hour.

Your physician will determine the duration of your treatment and how much CANCIDAS you will receive each day. He will monitor your response and condition. The dose will not need to be adjusted according to your age or if you are suffering from renal impairment. If you weigh more than 80 kg, a dose adjustment may be required.

If you take more CANCIDAS than you should

Your doctor will monitor your response and condition to determine what CANCIDAS treatment is needed. However, if you are concerned that you may have been given too much CANCIDAS, contact your doctor or another healthcare professional immediately.

If you miss/forget to take a dose of CANCIDAS

Your doctor will monitor your response and condition to determine what CANCIDAS treatment is needed. However, if you are concerned that you may have missed a dose, contact your doctor or another healthcare professional immediately.

If you stop taking CANCIDAS

There are no known withdrawal symptoms.

What are possible side effects?

Like all medicines, CANCIDAS can cause side effects, although not everybody gets them.

The following terms are used to describe how often side effects have been reported.

Very common (occurring in at least 1 in 10 patients treated)
Common (occurring in at least 1 of 100 and less than 1 of 10 patients treated)
Uncommon (occurring in at least 1of 1,000 and less than 1 of 100 patients treated) Rare (occurring in at least 1 of 10,000 and less than 1 of 1,000 patients treated)
Not known (cannot be estimated from the available data)

Adults 18 years of age or older:

Blood and lymphatic system disorders:
Uncommon: alterations in some laboratory blood tests (including decrease in red blood cell count)

Metabolism and nutrition disorders:
Common: low potassium levels in the blood
Uncommon: increase in amount of body fluid, loss of appetite, imbalance of salt in the body, low magnesium levels in the blood, high sugar level in the blood, low calcium level in the blood, increase in acid level in the blood

Psychiatric disorders:
Uncommon: nervousness, disorientation, inability to sleep

Nervous system disorders:
Common: headache
Uncommon: dizziness, taste disturbance, tingling or numbness, sleepiness, shaking, decreased feeling or sensitivity (especially in the skin)

Eye disorders:
Uncommon: yellowing of the whites of the eyes, blurred vision, swollen eyelid, increase in tears

Cardiac disorders:
Uncommon: sensation of fast or irregular heart beats, rapid heart beat, irregular heart beat, abnormal heart rhythm, heart failure

Vascular disorders:
Common: inflammation of vein
Uncommon: swelling and redness along a vein which is extremely tender when touched, flushing, hot flush, high blood pressure, low blood pressure

Respiratory, thoracic and mediastinal disorders:
Common: shortness of breath
Uncommon: blocked nose, pain in throat area, fast breathing rate, tightening of the bands of muscle around the airways resulting in wheezing or coughing, cough, shortness of breath that awakens the patient during sleep, shortage of oxygen in the body, crackling sounds in the lungs, wheezing

Gastrointestinal disorders:
Common: nausea, vomiting, diarrhoea
Uncommon: belly pain, upper belly pain, dry mouth, indigestion, stomach discomfort, bloating, swelling due to build-up of fluid around the belly, constipation, difficulty swallowing, passing gas

Hepatobiliary disorders:
Common: alterations in some laboratory blood tests (including increased values of some liver tests) Uncommon: decreased flow of bile, enlarged liver, yellowing of the skin and/or whites of the eyes, chemical-driven liver damage, liver disorder

Skin and subcutaneous tissue disorders: Common: rash, itching, excessive sweating, skin redness
Uncommon: red often itchy spots on the limbs and sometimes on the face and the rest of the body, rash of varying appearance, hives, generalised itching, abnormal skin tissue

Musculoskeletal and connective tissue disorders: Common: joint pain
Uncommon: back pain, pain in limb, bone pain, muscular weakness, muscle pain

Renal and urinary disorders:
Uncommon: loss of kidney function, sudden loss of kidney function

General disorders and administration site conditions:
Common: fever, chills, itching at the injection site
Uncommon: pain, catheter site pain, fatigue, injection site complaints (redness, hard lump, pain, swelling, irritation, rash, hives), inflammation of vein at injection site, swelling in limbs, tenderness, chest discomfort, chest pain, swelling of the face, feeling of body temperature change, generally feeling unwell, swelling

Investigations:
Common: alterations in some laboratory blood tests (including increased values of some kidney tests)

Children and adolescents (12 months to 17 years of age):

Nervous system disorders:
Common: headache

Cardiac disorders:
Common: rapid heart beat

Vascular disorders:
Common: flushing, low blood pressure

Hepatobiliary disorders: Common: alterations in some laboratory blood tests (increased values of some liver tests)

Skin and subcutaneous tissue disorders: Common: rash, itching

General disorders and administration site conditions:
Very common: fever
Common: chills, catheter site pain

Investigations:
Common: alterations in some laboratory blood tests

Possible histamine-mediated symptoms have been reported including reports of rash, swelling of the face and/or lips, and/or throat, itching, sensation of warmth, or trouble breathing.

Life-threatening allergic reactions that might include difficulty breathing with wheezing or worsening of an existing rash have also been reported rarely during administration of CANCIDAS. Other side effects may also occur rarely, and as with any prescription medicine, some side effects may be serious. Ask your doctor for more information.

If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.

How should it be stored?

Keep out of the reach and sight of children.

Do not use CANCIDAS after the expiry date which is stated on the carton and the vial. The first 2 numbers indicate the month; the next 4 numbers indicate the year. The expiry date refers to the last day of that month.

Store in a refrigerator (2°C to 8°C).

Reconstituted CANCIDAS should be used immediately because it does not contain any preservatives to prevent bacterial contamination. Only a trained health care professional who has read the complete directions (please see below “Instructions of how to reconstitute and dilute CANCIDAS”) can properly prepare this medicine for use.

↑ back to table of contents ↑

For doctors

What is it?

Cancidas is a powder that is made up into a solution for infusion (drip into a vein). It contains the active substance caspofungin.

What is it used for?

Cancidas is an antifungal medicine. It is used to treat adults, adolescents and children with:

How is it used?

Cancidas treatment should be started by a doctor who has experience in the management of invasive fungal infections. Cancidas must be made up into a solution before use, using a diluent that does not contain glucose.
It is given once a day by slow infusion lasting about one hour. In adults, treatment starts with a 70 mg loading dose, followed by a daily 50 mg dose, or 70 mg if the patient weighs more than 80 kg. A lower dose may be necessary in adults who have moderate problems with their liver. In patients between 12 months and 17 years of age, the dose depends on body surface area (calculated using the child’s height and weight). Cancidas should be used with caution in children below 12 months of age, because it has not been studied sufficiently in this age group.
Treatment is continued for up to two weeks after the infection has been cured.

How does it work?

The active substance in Cancidas, caspofungin, belongs to a group of antifungal medicines known as ‘echinocandins’. It works by interfering with the production of a component of the fungal cell wall called ‘glucan polysaccharide’, which is necessary for the fungus to continue living and growing. Fungal cells treated with Cancidas have incomplete or defective cell walls, making them fragile and unable to grow. The list of fungi against which Cancidas is active can be found in the Summary of Product Characteristics (also part of the EPAR).

How has it been studied?

Cancidas has been studied in five main studies.
Three studies looked at the effects of Cancidas in the treatment of invasive candidiasis or aspergillosis: one study involved 239 adults with invasive candidiasis, another involved 69 adults with invasive aspergillosis, and the third involved 49 patients aged between six months and 17 years with either candidiasis or aspergillosis. Cancidas was compared with amphotericin B given into a vein in the study of adults with invasive candidiasis.
For the empirical treatment of neutropenic febrile patients, Cancidas has been compared with amphotericin B in two studies: one involving 1,111 adults and another involving 82 patients aged between two and 17 years.
In all five studies, the main measure of effectiveness was the number of patients who responded to treatment. This is based on the improvement of their symptoms, as well as other criteria, such as elimination of the fungus from samples taken from the patients.

What benefits has it shown during the studies?

In invasive candidiasis, 73% of the adults treated with Cancidas who could be assessed had a favourable response (80 out of 109), compared with 62% of the adults treated with amphotericin B (71 out of 115).
In invasive aspergillosis, 41% of the adults had a favourable response at the end of the study (26 out of 63). Of the adults who did not respond to other treatments, 36% responded to Cancidas (19 out of 53). Of those who did not tolerate other treatments, 70% responded to Cancidas (7 out of 10). Similar responses were seen in children and adolescents: 50% of those with invasive candidiasis (5 out of 10) and 81% of those with invasive aspergillosis (30 out of 37) responded to Cancidas. In the empirical treatment of febrile neutropenic patients, Cancidas was as effective as amphotericin B. In the adult study, 34% of both groups of adults had a favourable response. Similar results were seen in the study of children and adolescents.

What is the risk associated?

The most common side effect with Cancidas (seen in more than 1 patient in 10) is fever. For the full list of all side effects reported with Cancidas, see the Package Leaflet.
Cancidas should not be used in people who may be hypersensitive (allergic) to caspofungin or any of the other ingredients.

Why has it been approved?

The Committee for Medicinal Products for Human Use (CHMP) decided that Cancidas’s benefits are greater than its risks for the treatment of invasive candidiasis or aspergillosis, and empirical therapy for presumed fungal infections, in adult or paediatric patients. The Committee recommended that Cancidas be given marketing authorisation.
Cancidas was originally authorised under ‘Exceptional Circumstances’, because limited information was available at the time of approval. As the company had supplied the additional information requested, the ‘Exceptional Circumstances’ ended on 29 September 2006.

Further information

The European Commission granted a marketing authorisation valid throughout the European Union for Caspofungin MSD to Merck Sharpe and Dohme Limited on 24 October 2001. The name of the medicine was changed to Cancidas on 9 April 2003. The marketing authorisation was renewed on 24 October 2006.

↑ back to table of contents ↑
 

Name

 

CANCIDAS 50 mg powder for concentrate for solution for
infusion

 

Composition

 

Each vial contains 50 mg caspofungin (as acetate).

Each 50 mg vial contains 35.7 mg of sucrose.

For a full list of excipients, see section 6.1.

 

Pharmaceutical Form

 

Powder for concentrate for solution for infusion.

White to off-white compact, lyophilised powder.

 

Are you an Healthcare Professional? Access professional drug leaflets on Diagnosia.com!

 

以下是“全球医药”详细资料
Tags: 责任编辑:admin
】【打印繁体】【投稿】【收藏】 【推荐】【举报】【评论】 【关闭】 【返回顶部
分享到QQ空间
分享到: 
上一篇CANCIDAS 70 mg powder for conce.. 下一篇Eremfat® 150 | -300 | -450 ..

相关栏目

最新文章

图片主题

热门文章

推荐文章

相关文章

广告位